

12 July 2016
EMA/HMPC/680625/2013
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Prunus africana* (Hook f.) Kalkm., cortex

Final

The European Medicines Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Andro MC, Riffaud JP. *Pygeum africanum* extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. *Curr Ther Res* 1995, 56:796–817

Barlet A, Albrecht J, Aubert A, Fischer M, Grof F, Grothuesmann JC, *et al.* Efficacy of *Pygeum africanum* extract in the treatment of micturitional disorders due to benign prostatic hyperplasia. Evaluation of objective and subjective parameters. A multicentre, randomized, double-blind trial. *Wien Klin Wochenschr* 1990, 102:667–673

Blumenthal M, Goldberg A, Brinckmann J (1999). *Echinacea purpurea* root. In: Herbal Medicine - Expanded Commission E monographs, American Botanical Council, Austin, TX, USA: 98-102

Bombardelli E, Morazzoni P. *Prunus africana* (Hook f.) Kalkm. *Fitoterapia* 1997, 68:205-218

Boulbès D, Soustelle L, Costa P, Haddoum M, Bali J-P, Hollande F, *et al.* *Pygeum africanum* extract inhibits proliferation of human cultured prostatic fibroblasts and myofibroblasts. *J Compilation* 2006, 98:1106–1113

Bruneton J. *Prunus africana*. In Pharmacognosie, Phytochimie, Plantes médicinales. Lavoisier, Paris 1999:161-162

Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of *Pygeum africanum* extract in patients with benign prostatic hyperplasia: a randomized, double-blind study with long-term open label extension. *Urology* 1999; 54:473-478

Chen MW, Levin RM, Horan P, Butyan R. Effects of unilateral Ischemia on the contractile response of the bladder Protective effect of tadenan (*Pygeum africanum* extract) *Mol urol* 1999, 3:5-10

Choo M-S, Bellamy F, Constantinou C E. Functional evaluation of Tadenan on micturition and experimental prostate growth induced with exogenous dihydrotestosterone. *Urology* 2000, 55:292-298

Clavert A, Cranz C, Riffaud JP, Marquer C, Lacelle JY, Bollack C. Effets d'un extrait d'écorce de *Pygeum africanum* (V.1326) sur les secretions prostatiques du rat et de l'homme. *Ann Urol* 1986, 20:341-343

Coulson S, Raoa A, Becka SL, Steels E, Gramotneva H, Vitetta L. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: A herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. *Compl Ther Med* 2013, 21:172-179

Cristoni A, Di Pierro F, Bombardelli E. Botanical derivatives for the prostate. *Fitoterapia* 2000, 71:S21-S28

DerMarderosian A, Beutler JA, editors. The Review of Natural Products. 4th ed. Facts & Comparisons, Saint Louis 2005, 942-944

Descazeaud A, Barry Delongchampsb N, Cornud J-N, Azzouzie A R, Buchonf D, et al. Guide de prise en charge en médecine générale des symptômes du bas appareil urinaire de l'homme liés à une hyperplasie bénigne de la prostate *Progrès en urologie* 2015, 25:404—412

Diz M. [*Pygeum africanum* in urologia]. *New Engl J Med* 1973, 7:35–38 [Spanish]

Dufour B, Choquenot C, Revol M, Faure G, Jorest R. Etude contrôlée des effets de l' extrait de *Pygeum africanum* sur les symptômes fonctionnels de l'adénome prostatique. *Ann Urol* 1984, 18(3) :193-195

Elgorashi EE, Taylor JLS, Maes A, Van Staden J, De Kimpe N, Verschaeve L. Screening of medicinal plants used in South African traditional medicine for genotoxic effects. *Toxicol Letts* 2003, 143:195–207

ESCOP Monographs 2nd ed. Pruni africanae cortex – Pygeum bark. European Scientific Cooperative on Phytotherapy, editor. Thieme Verlag, Stuttgart Supplement 2009, 206

European Pharmacopoeia. 8th ed. Pygeum africanum bark - Pruni africanae cortex. Council of Europe. 1/2015:1886

Fourneau C, Hocquemiller R, Cave A. Triterpenes from *Prunus africana* bark. *Phytochemistry* 1996, 42 (5):1387-1389

Gathumbi PK, Mwangi JW, Mugeru GM, Njiro SM. Toxicity of chloroform extract of *Prunus Africana* stem bark in rats: gross and histological lesions. *Phytother Res* 2002, 16:244-247

Gathumbi PK, Mwangi JW, Njiro SM, Mugeru GM. Biochemical and haematological changes in rats administered an aqueous extract of *Prunus africana* stem-bark at various dosage levels *Onderstepoort J Veterin Res* 2000, 67:123-128

Gomes CM, Disanto ME, Horan P, Levin RM, Wein AJ, Chacko S. Improved contractility of obstructed bladder after Tadenan treatment is associated with reversal of altered myosin isoform expression. *J Urol* 2000, 163:2008-2013

Gravas S, Bach T, Bachmann A, Drake M, Gacci M, Gratzke C, et al. Guidelines on the management of Non-Neurogenic male lower urinary tract symptoms (LUTS) incl. Benign Prostatic obstruction (BPO) *Eur Assoc Urol*, 2015:1-70

Gruenwald J, Brendler T, Jaenicke C, LaGow B, editors. PDR for Herbal Medicines. 4thed. Thomson PDR, Montvale 2007, 679-682

Hass MA, Nowak DM, Leonova E, Levin RM, Longhurst PA. Identification of components of *Prunus africana* extract that inhibit lipid peroxidation. *Phytomedicine* 1999, 6:379-388

- Hutchison A, Farmer R, Verhamme K, Berges R, Vela Navarrete R. The Efficacy of Drugs for the Treatment of LUTS/BPH, A Study in 6 European Countries *Eur Urol* 2007, 51: 207–216
- Ishani A, MacDonald R, Nelson D, Rutks I, Wilt TJ. *Pygeum africanum* for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. *Am J Med* 2000, 109:654-664
- Levin RM, Whitbeck C, Horan P. Low-dose Tadenan protects the rabbit bladder from bilateral Ischemia/reperfusion-induced contractile dysfunction. *Phytomedicine* 2005, 12(1-2):17-24
- Levin RM, Hass MA, Bellamy F, Horan P, Whitebeck K, Chow PH, *et al.* Effect of oral tadenan treatment on rabbit bladder structure and function after partial outlet obstruction. *J Urol* 2002, 167:2253–2259
- Levin RM, Riffaud JP, Bellamy F, Rohrmann D, Habib M, Krasnopolsky M, *et al.* Protective effect of Tadenan on Bladder function secondary to partial outlet obstruction. *J Urol* 1996, 155(4):1466-1470
- Lowe FC, Ku JC. Phytotherapy in the treatment of benign prostatic hyperplasia: a critical review. *Urology* 1996, 48:12–20
- Marcoli M, D'Angelo L, Del Vecchio A, Caravaggi M, Lecchini S, Frigo GM, *et al.* Anti inflammatory action of *pygem africanum* extract in rat. *Farmaci & Terapia* 1986, III(2):135-137
- Mwitari PG, Ayeka PA, Ondicho J, Matu EN, Bii CC. Antimicrobial Activity and Probable Mechanisms of Action of Medicinal Plants of Kenya: *Withania somnifera*, *Warbugia ugandensis*, *Prunus africana* and *Plectranthus barbatus*. *Plos One* 2013, 8(6):e65619
- Nicholson TN, Ricke WA. Androgens and oestrogens in benign prostatic hyperplasia: Past, present and future. *Differentiation* 2011, 82(4-5):184–199
- Papaioannou M, Schleich S, Roell D, Schubert U, Tanner T, Claessens T, *et al.* NBBS isolated from *Pygeum africanum* bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth. *Invest New Drugs* 2010, 28(6):729-743
- Quiles MT, Arbós MA, Fraga A, de Torres IM, Reventós J, Morote J. Antiproliferative and Apoptotic Effects of the Herbal Agent *Pygeum africanum* on Cultured Prostate Stromal Cells From Patients With Benign Prostatic Hyperplasia (BPH). *Prostate* 2010, 70:1044-1053
- Reid KA, Maes J, Maes A, Van Staden J, De Kimpe N, Mulholland DA, *et al.* Evaluation of the mutagenic and antimutagenic effects of South African plants. *J Ethnopharmacol* 2006, 106:44–50
- Riffaud JP, Lacolle JY. Effects of Tadenan on the detrusor smooth muscle of young and old rats. *Eur Urol* 1990, 18:309–312
- Roell D, Baniahmad A. The natural compounds atraric acid and N- butylbenzene-sulfonamide Antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. *Mol Cel Endocrinol* 2011, 332(1-2):1-8
- Schleich S, Papaioannou M, Baniahmad A, Matusch R. Activity-guided isolation of anantiandrogenic compound of *Pygeum africanum*. *Planta Med* 2006a, 72(6):547-551
- Schleich S, Papaioannou M, Baniahmad A, Matusch R. Extracts from *Pygeum africanum* and other ethnobotanical species with antiandrogenic activity. *Planta Med* 2006b, 72(9):807-813
- Schmidt M, Polednik C, Roller J, Hagen R. Cytotoxicity of herbal extracts used for treatment of prostatic disease on head and neck carcinoma cell lines and non-malignant primary mucosal cells. *Oncol Reports* 2013, 29:628-636

Shenouda NS, Sakla MS, Newton LG, Besch-Williford C, Greenberg NM, MacDonald RS, *et al.* Phytosteril *Pygeum africanum* regulates prostate cancer *in vitro* and *in vitro*. *Endocr* 2007, 31:72-81

Steenkamp V. Phytomedicines for the prostate. *Fitoterapia* 2003, 74:545–552

Taylor JLS, Elgorashi EE, Maes A, Van Gorp U, De Kimpe N, Van Puyvelde L, *et al.* Investigating the safety of plants used in South African traditional medicine—testing for genotoxicity in the micronucleus and alkaline Comet assays. *Environ Mol Mutagen* 2003, 42:144–154

Verschaeve L, Kestens V, Taylor JLS, Elgorashi EE, Maes A, Van Puyvelde L, *et al.* Investigation of the antimutagenic effects of selected South African medicinal plant extracts. *Toxicology in Vitro* 2004, 18(1):29-35

Verschaeve L, Van Staden J. Mutagenic and antimutagenic properties of extracts from South African traditional medicinal plants. *J Ethnopharmacol* 2008, 119(3):575-587

Wang D, Li Y, Hou G, Wang P, Zhang J, Laudon V, *et al.* *Pygeum africanum*: effect on oxidative stress in early diabetes-induced bladder. *Int Urol Nephrol* 2010, 42:401-408

WHO Monographs on Selected Medicinal Plants. Vol 2. *Pygeum africanum*. World Health Organization, Geneva 2009, 83-91

Wilt T J, Ishani A. *Pygeum africanum* for benign prostatic hyperplasia (Review). The Cochrane Collaboration and published in The Cochrane Library, 2011, Issue 1

Yablonsky F, Nicolas V, Riffaud P, Bellamy F. Antiproliferative effect of *Pygeum africanum* extract on rat prostatic fibroblasts. *J Urol* 1997, 157:2381-2387

Yongzhi L, Benkang S, Jianping Z, Lingxia R, Wei B, Yaofeng Z, *et al.* The expression of transforming growth factor b1 gene, basic fibroblast growth factor gene and hydroxyproline in diabetes –induced bladder dysfunction in a rat model. *Neurourol Urodyn* 2008, 27(3):254-259

Yoshimura Y, Yamaguchi O, Bellamy F, Constantinou CE. Effect of *Pygeum africanum* Tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. *Urology* 2003, 61:474-478

References used but not cited in the AR

Edgar A D, Levin R, Constantinou C E, Denis L. A Critical review of the Pharmacology of the plant *Pygeum africanum* in the treatment of LUTS. *Neurorol Urodyn* 2007, 26:458-463

Larre S, Camparo P, Comperat E, Boulbe D, Haddoum H, Baulande S, *et al.* Biological effect of human serum collected before and after oral intake of *Pygeum africanum* on various benign prostate cell cultures. *Asian J Andrology* 2011, 1–6

Mathé G *et al.* The so-called phyto-estrogenic action of *Pygeum africanum* extract. *Biome Pharmacother* 1995, 49:339–340

McConnell J D, Roehrborn C G, Bautista O M, Andriole G L, Dixon C M, *et al.* The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia 2003 *The New Engl J. Med* 349 (25)

Moya-Prats PP, Salvá Verd A, Crespi Mesquida G. Valoración estadística de 500 pacientes con hipertrofia prostática benigna, tratados con *Pygeum africanum*, y valorados estadísticamente desde el punto de vista clínico y flujométrico. *Urodinám Aplicad* 1989, 1:150–155

Paubert-Braquet M, *et al.* Effect of *Pygeum africanum* extract on A23187-stimulated production of lipooxygenase metabolites from human polymorphonuclear cells. *J Lipid Med Cell Signal* 1994, 9:285–290 (only abstract)

Paubert-Braquet M, Monboissc JC, Scrvent-Saez N, Serikoff A, Cave A, Hocquemiller R, *et al.* Inhibition of bFGF and EGF-induced proliferation of 3T3 fibroblasts by extract of *Pygeum africanum* (Tadenan®). *Biomed Pharmacother* 1994, 48(Suppl1):43s-47s (only abstract)

Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008 *B J U Int* 2011; 10 9 , 84–87 | doi:10.1111/j.1464-410X.2011.10250.x

Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. *Serenoa repens* for benign prostatic hyperplasia. *Cochrane Database Syst. Rev.* DOI: 10.1002/14651858.CD001423.pub3